ReviewFrontiers in oncology2021
A Review of the Clinical Characteristics and Novel Molecular Subtypes of Endometrioid Ovarian Cancer.
Review in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 1 synthesis or guideline pooled it, 45 citations in OpenAlex.
- Homologous Recombination Deficiency Testing to Inform Patient Decisions About Niraparib Maintenance Therapy for High-Grade Serous or Endometrioid Epithelial Ovarian Cancer: A Health Technology Assessment.Ontario health technology assessment series · 2023Pooled it
- Deciphering the Pleiotropic Role ofCells · 2026Article
- STAT1 and STAT3 signaling in ovarian cancer: prognostic biomarkers and therapeutic targets.BMC cancer · 2026Article
- Discordant p53 and BRG1 expression in synchronous low-grade uterine endometrioid carcinoma and SMARCA4-deficient ovarian undifferentiated carcinoma: a case report.BMC women's health · 2026Article
- Ovarian cancer.Nature reviews. Disease primers · 2026Review
- Targeting Autophagy in Ovarian Cancer: The Emerging Role of Ginsenosides.Cancer medicine · 2026Review
- Regulation of E-cadherin by mixed lineage kinase 3 (MLK3) mediates cell adhesion in ovarian cancer spheroids.Biochimica et biophysica acta. Molecular cell research · 2026Article
- Mendelian randomization study of GLP-1R effects on ovarian cancer subtypes mediated by metabolic factors.Communications medicine · 2026Article
- Ovarian Tumor Biomarkers: Correlation Between Tumor Type and Marker Expression, and Their Role in Guiding Therapeutic Strategies.International journal of molecular sciences · 2025Review
- Identifying At-Risk Populations for Treatment Delays in Endometrioid Ovarian Carcinoma: A Nationally Representative Study.Biomedicines · 2025Article
- Prediction of grading of ovarian endometrioid carcinoma using conventional MRI features.Japanese journal of radiology · 2025Article
- BET inhibitor JQ1 induces apoptosis of ovarian and endometrial endometrioid carcinoma cells by downregulatingOncology letters · 2025Article
- Early Diagnosis of Ovarian Cancer: A Comprehensive Review of the Advances, Challenges, and Future Directions.Diagnostics (Basel, Switzerland) · 2025Review
- Decoding immune low-response states in ovarian cancer: insights from single-cell and spatial transcriptomics for precision immunotherapy.Frontiers in immunology · 2025Review
- Prognostic and predictive significance of the pan-immune-inflammation value in endometrial cancer patients undergoing adjuvant therapy.Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology · 2025Article
- Review
- Association between gynecologic cancer and Alzheimer's disease: a bidirectional mendelian randomization study.BMC cancer · 2024Article
- Spatial tumor immune microenvironment phenotypes in ovarian cancer.NPJ precision oncology · 2024Article
- Article
- Outcomes after fertility-sparing surgery of early-stage ovarian cancer: A nationwide population-based study.Cancer medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ovarian cancer is one of the most common gynecologic cancers that has the highest mortality rate. Endometrioid ovarian cancer, a distinct subtype of epithelial ovarian cancer, is associated with endometriosis and Lynch syndrome, and is often accompanied by synchronous endometrial carcinoma. In recent years, dysbiosis of the microbiota within the female reproductive tract has been suggested to be involved in the pathogenesis of endometrial cancer and ovarian cancer, with some specific pathogens exhibiting oncogenic having been found to contribute to cancer development. It has been shown that dysregulation of the microenvironment and accumulation of mutations are stimulatory factors in the progression of endometrioid ovarian carcinoma. This would be a potential therapeutic target in the future. Simultaneously, multiple studies have demonstrated the role of four molecular subtypes of endometrioid ovarian cancer, which are of particular importance in the prediction of prognosis. This literature review aims to compile the potential mechanisms of endometrioid ovarian cancer, molecular characteristics, and molecular pathological types that could potentially play a role in the prediction of prognosis, and the novel therapeutic strategies, providing some guidance for the stratified management of ovarian cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.